EZH2 and myeloid neoplasm: After multivariable adjustment, considering the type of treatment (intensive or non-intensive), the disease (AML or non-AML myeloid neoplasm), and the presence of del(7q)/-7, the presence of an EZH2 mutation was associated with a trend towards an increased risk of death (hazard ratio (HR) 2.51 [95% confidence interval (CI) 0.87–7.25], p = 0.09); similarly, low EZH2 protein expression was associated with elevated risk (HR 2.54 [95% CI 1.07–6.04], p = 0.04).